C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61M 5/24 - Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic
The present invention relates to the treatment of subjects having a CD20-positive cell proliferative disorder. More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The instant technology generally relates to improved methods for producing antibodies, antibody libraries, hybridomas, hybridoma libraries, etc. For example, these methods increase the number of antigen-specific B cells produced, increase the number of hybridomas, and/or increase the number of monoclonal antibodies that can be made in a given production cycle.
The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, non-small cell lung cancer (NSCLC). The invention provides methods of treating NSCLC, methods of determining whether a patient suffering from NSCLC is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from NSCLC to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from NSCLC, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor cells and/or tumor-infiltrating immune cells).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
5.
TREATMENT OF CANCER USING COMBINATION THERAPIES COMPRISING GDC-6036 and GDC-0077
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by intravenous administration of an anti-CD20/anti-CD3 bispecific antibody (e.g., mosunetuzumab).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 39/00 - Medicinal preparations containing antigens or antibodies
41 - Education, entertainment, sporting and cultural services
Goods & Services
Ophthalmic surgery devices and instruments for controlled sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; medical and veterinary apparatus and instruments for controlled drug delivery during ophthalmic surgery; ophthalmic apparatus and instruments, namely, surgical instruments for use in delivery and administration of fluid, biologics and pharmaceuticals during ophthalmic surgery; apparatus and instruments for treating the eye, namely, cannulas and needles for obtaining sub-retinal access for delivery of pharmaceutical and biologic preparations in the sub-retinal space; apparatus and instruments for treating the eye, namely, cannulas and needles for delivery of pharmaceutical and biologic preparations in the suprachoroidal space; apparatus and instruments for dispensing or delivering preparations into the eye or structures thereof, namely, devices for sub-retinal delivery via suprachoroidal space of pharmaceutical and biologic, cell therapy and gene therapy products; cannulas and needles for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; adhesive pads to provide stabilization for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; magnetic pads to provide stabilization for sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space Training services in the field of ophthalmic surgical procedures; training services in the field of ophthalmic surgical equipment and the use and operation thereof; educational services, namely, conducting in-person classes, seminars, conferences, exhibits, and workshops in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, conducting online classes, seminars, conferences, exhibits, and workshops in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, providing in-person instruction in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; educational services, namely, providing online instruction in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; interactive in-person training services in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment; interactive online training services in the field of ophthalmic surgery, ophthalmic surgical procedures, and the use and operation of ophthalmic surgical equipment
8.
GENERATIVE PROTEIN DESIGN WITH SMOOTHED ENERGY-BASED MODELS
A training set may be generated to include a plurality of noisy sample sequences. Each noisy sample sequence in the training set may be generated by adding noise to a corresponding sample sequence from a data distribution. A protein design computation model may be trained by at least applying the protein design computation model to generate one or more output sequences, and adjusting the protein design computation model to reduce a difference between the one or more output sequences and the plurality of noisy sample sequences in the first training set. The trained protein design computation model may be applied to generate an output sequence by at least modifying an input sequence.
The present invention provides compositions comprising a Fc-containing protein wherein substantially all the Fc domains have a C-terminal lysine. Further provided are host cell for producing said compositions, methods of making said host cells and compositions, and method of use thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Methods for the generative design of small molecules include performing, until one or more conditions are satisfied, one or more iterations of a generative algorithm. Each iteration of the generative algorithm may include modifying one or more molecules from an initial population of molecules. Moreover, each iteration of the generative algorithm may include selecting, from the initial population of molecules and the one or more modified molecules, a quantity of molecules satisfying one or more fitness scores for inclusion in a subsequent population of molecules. If the one or more conditions are not satisfied, one or more additional iterations of the generative algorithm may be performed using a different initial population of molecules or the subsequent generation of molecules as a new initial population of molecules. Related systems and computer program products are also provided.
Provided are combination therapies comprising a PI3K inhibitor (e.g., inavolisib), a CDK4/6 inhibitor (e.g., palbociclib), and fulvestrant; and methods of treating hormone receptor positive and HER2 negative (HR+/HER2−) locally advanced or metastatic breast cancer in a patient (preferably a patient with a PIC3CA mutant patient) comprising administering a therapeutically effective amount of inavolisib, or a pharmaceutically acceptable salt thereof, a CDK4/6 inhibitor (e.g., palbociclib), and fulvestrant or letrozole.
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
MACHINE LEARNING ENABLED LONGITUDINAL ANALYSIS OF POSITRON EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY SCANS FOR ASSESSMENT OF DISEASE PROGRESSION AND TREATMENT RESPONSE
A method may include determining, based on a first positron emission tomography (PET) scan and a first computed tomography (CT) scan from a first timepoint, a first tumor mask corresponding to a first lesion present in the first PET scan and the first CT scan. A second tumor mask corresponding to a second lesion present in the second PET scan and the second CT scan may be determined based on the second PET scan and the second CT scan from a second timepoint. A longitudinal segmentation model may be applied to update, based on the first PET scan, the first CT scan, the second PET scan, and the second CT scan, each of the first tumor mask and the second tumor mask. A response to a treatment for a disease may be determined based on at least one of the first updated tumor mask and the second updated tumor mask. Related systems and computer program products are also provided.
G06T 7/33 - Determination of transform parameters for the alignment of images, i.e. image registration using feature-based methods
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
University of Pittsburgh - Of the Commonwealth System of Higher Education (USA)
Genentech, Inc. (USA)
Inventor
Capogrosso, Marco
Eliasson, Mikael John Lars
Prat Ortega, Genis
Abstract
Disclosed herein are methods for treating spinal muscular atrophy in a subject. Particular methods comprise applying a therapeutically effective amount of an electrical stimulus to sensory neurons innervating a body region of the subject with a motor impairment due to the spinal muscle atrophy, wherein application of the electrical stimulus treats the motor impairment due to spinal muscular atrophy in the subject; in conjunction with administering an SMA therapy.
The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
16.
METHODS OF MAKING FUCOSYLATED AND AFUCOSYLATED FORMS OF A PROTEIN
C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
The disclosure provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CDS) bispecific antibodies (e.g., cevostamab).
The present invention provides in vitro, in silico, and in vivo methods, and combinations thereof, for optimizing dosages of combination therapies for treating cancer. The present invention additionally provides therapeutic methods and compositions for treating cancer using optimized dosages of the combination therapies.
Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
This present disclosure relates to machine learning-based methods and systems for making cell type- and cell state-specific predictions of gene expression for a given input DNA sequence, and for designing and/or optimizing DNA regulatory elements. In some instances, for example, the disclosed methods for predicting gene expression levels from genomic sequence data can comprise: receiving genomic sequence data comprising a DNA sequence for a specified gene; inputting the genomic sequence data to a trained machine learning model, wherein the trained machine learning model is: (i) trained on single cell gene expression data for a plurality of cell types and cell states, and (ii) configured to process genomic sequence data and predict a cell-type-specific and/or a cell-state-specific gene expression level; and outputting a prediction of a cell-type-specific and/or a cell-state-specific gene expression level for the specified gene.
Systems and methods for performing automated retinal segmentation. Initial imaging data that is associated with a target domain is received. The initial imaging data captures a retina. An image input for a machine learning model using the initial imaging data is formed. A segmentation output that graphically locates a set of retinal elements with respect to the initial imaging data is generated via the machine learning model. The machine learning model has been trained using a loss function that combines a supervised learning loss and a contrastive learning loss. The machine learning model has been trained using a training dataset that includes labeled imaging data associated with a set of source domains, the set of source domains being different from the target domain.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The current invention relates to antibodies, which bind to human vascular endothelial growth factor (VEGF) and human angiopoietin-2 (ANG2) for use in the treatment of ocular vascular diseases. Specifically, the invention relates to a method of preventing or reducing epiretinal membrane (ERM) formation in an eye of a patient by administering a bispecific antibody which binds to VEGF and to ANG-2.
The invention provides methods and compositions for treating cancer and for enhancing immune function in an individual having cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof, that are degraders of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
31.
TMEM175 MODULATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
The present application provides compounds of Formula (I) and Formula (II) (I), (II), and pharmaceutically acceptable salts thereof, that are modulators of TMEM175. Also provided are pharmaceutical compositions of the subject compounds, and methods of treating neurodegenerative disorders using the same.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
32.
OXADIAZOLE MODULATORS OF TMEM175 FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
This application provides compounds of formula (I) and formula (II) and pharmaceutically acceptable salts thereof, that are oxadiazole modulators of TMEM175. Also provided herein are pharmaceutical compositions thereof, and methods of treating neurodegenerative disorders using the same.
The current invention relates to antibodies, which bind to human vascular endothelial growth factor (VEGF) and human angiopoietin-2 (ANG2) for use in the treatment of ocular vascular diseases. Specifically, the invention relates to a method of preventing or reducing epiretinal membrane (ERM) formation in an eye of a patient by administering a bispecific antibody which binds to VEGF and to ANG-2.
A molecular analysis model may be trained to generalize across multiple molecular geometries by modifying a three-dimensional structure of one or more conformers of a molecule to generate. for each conformer. a plurality of augmented samples. The molecular analysis model may be trained to generate an embedding for each augmented sample while minimizing a difference between the plurality of embeddings resulting therefrom. Furthermore. the molecular analysis model may be trained to determine, based at least on the plurality of embeddings. a value of a molecular property for the molecule. The trained molecular analysis model may be applied in the determination of the value of the molecular property for another molecule.
Provided herein are methods of treating B-cell proliferative disorders (such as Follicular Lymphoma “FL”) using immunoconjugates comprising anti-CD79b antibodies in combination with an immunomodulatory agent (such as lenalidomide) and an anti-CD20 antibody (such as obinutuzumab or rituximab).
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided herein are methods of treating KRAS G12C-positive NSCLC by administering a combination of a KRAS G12C inhibitor and pembrolizumab with a prophylactic dose of a steroid.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure relates to eukaryotic cell lines with a stable integrated loss-of-function or attenuation-of-function mutation in each of the Bax and Bak genes. Also provided are methods of producing such cell lines. This disclosure also relates to compositions and cell cultures comprising such cell lines, as well as methods of producing a product, such as a recombinant polypeptide or viral vector, using said cells, compositions and cell cultures.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
C12N 15/67 - General methods for enhancing the expression
Provided herein are methods of treating KRAS G12C-positive NSCLC by administering a combination of a KRAS G12C inhibitor and pembrolizumab with a prophylactic dose of a steroid.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to the treatment of cell proliferative disorders. More specifically, the invention relates to the specific treatment of human subjects having a solid tumor malignancy using anti-C-C motif chemokine receptor 8 (CCR8)/anti-cluster of differentiation 3 (CD3) bispecific antibodies alone or in combination with an anti-programmed death-ligand 1 (PD-L1) antibody (e.g., atezolizumab).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided herein are combination therapies comprising a SHP2 inhibitor (e.g., Compound 1) and an EGFR inhibitor (e.g., osimertinib or cetuximab) and methods of using such combination therapies.
A method may include applying a protein design computation model to generate an output sequence and an output three-dimensional structure of an output protein molecule by jointly denoising an input sequence and an input three-dimensional structure of an input protein molecule. The joint denoising may include modifying the input sequence by inserting, deleting, or changing the type of one or more constituent amino acid residues while performing corresponding updates to the positions of the atoms in each amino acid residue. The protein design computation model may operate on a fixed size representation of the input protein molecule. Prior and/or subsequent to the joint denoising, the protein design computation model may modify the input three-dimensional structure to conform to bond constraints. Moreover, an informative prior data distribution may be incorporated by training the protein design computation model on training samples with noise sampled from the informative prior data distribution.
This present disclosure relates to immunology, particularly methods of predicting whether a therapeutic protein is likely to trigger an immunogenic response. An example method for predicting an amino acid-immunoprotein complex (IPC) interaction may comprise: accessing a set of amino acid sequences; accessing an immunoprotein complex (IPC) sequence identified for an IPC of a subject; processing a set of amino acid sequence representations to generate a set of transformed amino acid sequence representations based on a set of element-focused scores representing binding cores of the set of amino acid sequence representations; processing an IPC sequence representation to generate a transformed IPC sequence representation; generating composite representations; and determining one or more predicted amino acid-IPC interactions based on the composite representations.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
48.
SYSTEMS AND METHODS FOR VERIFYING LARGE LANGUAGE MODEL OUTPUT USING LOGIC RULES
The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.
The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 413/08 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.
The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The present disclosure provides anti-MerTK antibodies and methods of use thereof. The methods comprise administering an anti-MerTK antibody or an immunoconjugate thereof.
Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided.
The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
55.
ZIFIBANCIMIG FOR USE IN METHODS FOR TREATING OCULAR DISEASES
The present invention relates to to zifibancimig for the treatment of an ocular disease in a patient, wherein the zifibancimig is administered at a dose of up to 0.5 mg/eye, methods of treating ocular diseases using zifibancimig as well as pharmaceutical compositions comprising zifibancimig for treatment of ocular diseases.
The present invention relates to to zifibancimig for the treatment of an ocular disease in a patient having an ocular implant, wherein the zifibancimig is administered at a concentration of about 5 to about 160 mg/ml, methods of treating ocular diseases using zifibancimig as well as pharmaceutical compositions comprising zifibancimig for treatment of ocular diseases.
The present disclosure relates to plasmids that may be used to promote prolonged expression of recombinant proteins in vivo, such as in animal models, and their methods of construction and use, for instance in animals. In some embodiments, the plasmids, following injection into an animal, are converted to minicircles by recombination, such as in the liver of the animal.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Genetic identity tests comprised of reagents for medical purposes; Diagnostic preparations for medical purposes for detecting genetic predispositions; Preparations for detecting genetic predispositions for medical purposes; Reagents for use in medical genetic testing; Diagnostic biomarkers for use in assessment of genomic analysis for medical use; Diagnostic preparations for use in assessment of genomic analysis for medical use Genetic testing for scientific research purposes; Genetic mapping for scientific purposes; Consulting services in the field of genetic science; Providing medical research information in the field of genetics; Chemical, biochemical, biological and bacteriological research and analysis; Genotyping services for research or analysis purposes; Biological research and analysis; Biochemical research and analysis
59.
METHODS OF TREATING CANCER USING SUBCUTANEOUS DOSING OF MOSUNETUZUMAB AS A MONOTHERAPY OR IN COMBINATION WITH LENALIDOMIDE
The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas or chronic lymphocytic leukemia). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by subcutaneous administration of mosunetuzumab as a monotherapy or in combination with lenalidomide.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61P 35/02 - Antineoplastic agents specific for leukemia
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 9/00 - Medicinal preparations characterised by special physical form
This disclosure relates to methods of optimizing glycosylation of a recombinant polypeptide. Also provided are methods of optimizing charge pattern of a recombinant polypeptide. Also provided are methods of optimizing size distribution of a recombinant polypeptide. The methods comprise modulating the level of B vitamins in a cell culture comprising a cell line engineered to express the recombinant polypeptide.
61.
METHODS OF PREDICTING AND MITIGATING TRYPTOPHAN OXIDATION
Provided herein are methods of determining whether a tryptophan residue of a polypeptide is likely to be oxidized, methods of modifying a polypeptide comprising a tryptophan residue (e.g., an unstable tryptophan residue) to reduce the likelihood of oxidation of the tryptophan residue, and polypeptides produced by such methods.
The present invention relates to lyophilized and frozen pharmaceutical formulations comprising a nucleic acid (NA)-lipid nanoparticle (LNP) particle, wherein the NA-LNP particle comprises a nucleic acid encapsulated in the lipid nanoparticle, wherein the formulation further comprises an excipient comprising a lyoprotectant or cryoprotectant and a buffer, and wherein the lyoprotectant or cryoprotectant is a polyvinylpyrrolidone (PVP) or a polyethylene glycol (PEG). Methods of making the lyophilized and frozen formulations are also provided.
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
A61K 9/19 - Particulate form, e.g. powders lyophilised
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
64.
DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES
The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
65.
METHODS FOR TREATING PULMONARY FIBROTIC DISEASES OR DISORDERS WITH AN ANTI-ONCOSTATIN M RECEPTOR BETA ANTIBODY
The disclosure provides methods for treating pulmonary fibrotic disorders, including idiopathic pulmonary fibrosis, by administering to patients therapeutically effective doses and dosing regimens of an anti-OSM receptor β antibody, such as vixarelimab, or anti-OSM receptor β antibody, such as vixarelimab, in combination with an anti-IL-6 antibody or an anti-IL-6 receptor agonis, such as tocilizumab.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Apparatus, systems, computer-readable media, articles of manufacture and methods for selecting an antibody. Apparatus, systems, computer-readable media, articles of manufacture and methods for producing the selected antibody. The selecting may include determining one or more physiochemical characteristics of the antibody. The determining may be based on antibody structural parameters.
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
G01N 33/531 - Production of immunochemical test materials
G16B 35/00 - ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
A method may include determining, based at least on a knowledge graph, a plurality of biological interaction profiles associated with a plurality of drugs. The knowledge graph being representative of a plurality of interactions between a variety of drugs, proteins, and a hierarchy of biological functions. Each biological interaction profile may be representative of the effects of a corresponding drug being propagated through protein-protein interactions and biological functions. A liver injury prediction model may be trained, based on a training dataset including the biological interaction profiles, a probability of drug induced liver injury. The liver injury prediction model to may be applied to determine, based on the biological interaction profile of a drug, the probability of liver injury associated with the drug. In some cases, the liver injury prediction model may further determine the probability of liver injury based on the molecular fingerprint and/or the molecular properties of the drug.
Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions.
Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions.
Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions.
Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.
C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07D 471/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed systems contains four or more hetero rings
C07D 491/147 - Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
The invention provides stable aqueous pharmaceutical formulations comprising an anti-PDL1 antibody. The invention also provides methods for making such formulations and methods of using such formulations.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Provided herein are engineered adeno-associated virus (AAV) capsids having altered (e.g., increased) affinity for AAV receptor (AAVR); methods of using the same; and methods of determining the affinity of an AAV capsid for a query protein using virus-like particles (VLPs) having a capsid consisting of the VP3 subunit of the AAV capsid.
The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Systems and methods relate to predicting disease progression by processing digital pathology images using neural networks. A digital pathology image that depicts a specimen stained with one or more stains is accessed. The specimen may have been collected from a subject. A set of patches are defined for the digital pathology image. Each patch of the set of patches depicts a portion of the digital pathology image. For each patch of the set of patches and using an attention-score neural network, an attention score is generated. The attention-score neural network may have been trained using a loss function that penalized attention-score variability across patches in training digital pathology images labeled to indicate no or low subsequent disease progression. Using a result-prediction neural network and the attention scores, a result is generated that represents a prediction of whether or an extent to which a disease of the subject will progress.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The presently disclosed subject matter relates to targeted integration (TI) host cells suitable for the expression of recombinant proteins wherein those TI host cells have been subjected to supertransfection resulting in the random integration (RI) of exogenous nucleic acids encodes into their genome, as well as methods of producing and using said supertransfected TI host cells.
The invention provides methods of identifying a subject having cancer, such as lung cancer, by analyzing expression levels of one or more NRF2 splice variants or NRF2 target genes. The invention also provides methods of treating cancer in a subject with a NRF2 pathway antagonist, wherein the subject expresses one or more NRF2 splice variants or overexpresses one or more NRF2 target genes.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present disclosure provides methods and compositions for treating inflammatory bowel disease (IBD), e.g., ulcerative colitis (UC) or Crohn's disease (CD), with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
77.
USE OF ATR INHIBITORS IN COMBINATION WITH RADIOLIGAND THERAPY FOR THE TREATMENT OF CANCER
Disclosed are methods of treating a cancer in a subject using at least one ATR inhibitor and a radionuclide-containing PSMA targeting agent such as 177Lu vipivotide tetraxetan, wherein the cancer has an over expression of PSMA on its cell membrane. The methods comprise contacting the cell with a therapeutically effective amount of a combination of at least one ATR inhibitor and 177Lu vipivotide tetraxetan.
A method is provided for coating tablets on-demand in a miniaturized coating apparatus. A supply of tablets are provided, each having dimensions and a mass. The supply of tablets together has a total number, a total mass and a total volume. In some aspects, specifications are selected for constructing a customized rotatable drum based on tablet dimensions, tablet number, total mass, total volume, physical and/or chemical properties of coating material(s) to be applied to the tablets, or a combination thereof. In some embodiments, the rotatable drum may be formed by 3D printing.
A61J 3/00 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
B01J 2/12 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic in rotating drums
B05B 13/02 - Means for supporting workArrangement or mounting of spray headsAdaptation or arrangement of means for feeding work
79.
COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS
The invention provides methods for treating or delaying progression of lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. The invention also provides methods for treating or delaying progression of rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) in an individual. In some embodiments, the methods comprise administering an effective amount of an anti-CD20 antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
80.
NUCLEI-BASED DIGITAL PATHOLOGY SYSTEMS AND METHODS
Systems and methods for predicting the therapeutic response of a specified disease therapy for individual patients based on an analysis of digital pathology images are described. In some instances, for example, the disclosed methods can comprise: receiving an image of a tumor specimen from a patient; segmenting the image to identify tumor cell nuclei; generating a feature vector that includes a plurality of features, each corresponding to a statistical measure of one of a set of morphological parameters used to characterize the tumor cell nuclei; and providing the generated feature vector as input to a trained machine-learning model configured to output a prediction of the therapeutic response of the specified disease therapy for the patient.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G06V 10/26 - Segmentation of patterns in the image fieldCutting or merging of image elements to establish the pattern region, e.g. clustering-based techniquesDetection of occlusion
G06V 10/40 - Extraction of image or video features
G06V 10/77 - Processing image or video features in feature spacesArrangements for image or video recognition or understanding using pattern recognition or machine learning using data integration or data reduction, e.g. principal component analysis [PCA] or independent component analysis [ICA] or self-organising maps [SOM]Blind source separation
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
81.
METHODS OF TREATING PANCREATIC CANCER WITH A PD-1 AXIS BINDING ANTAGONIST AND AN RNA VACCINE
The present disclosure provides methods for treating an individual with pancreatic cancer with an individualized cancer vaccine and a PD-1 axis antagonist.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
C07K 14/74 - Major histocompatibility complex [MHC]
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
82.
ANCESTRY-RELATED KRAS CO-ALTERATION PATTERNS AS PROGNOSTIC BIOMARKERS
Biomarker-based methods for predicting disease prognosis and treatment outcomes are described. In some instances, the disclosed methods can comprise, for example, detecting in a sample from the subject, a KRAS gene alteration; detecting, in the sample from the subject, at least one of a STK11 gene alteration or a KEAP1 gene alteration; and predicting a prognosis and/or treatment outcome for the subject based on the detection of a co-alteration of the KRAS gene and at least one of the STK11 and/or KEAP1 genes. In some instances, the disease may be cancer, e.g., non-squamous non-small cell lung cancer (NSCLC). In some instances, the prediction of treatment outcomes may comprise prediction of treatment outcomes when treating a cancer (e.g., NSCLC) with an immune checkpoint inhibitor (ICI) or a KRAS G12C inhibitor.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
83.
COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR
The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
09 - Scientific and electric apparatus and instruments
35 - Advertising and business services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable computer software for health and medical data analysis and downloadable computer software for use in identifying patients who may have had respiratory or pulmonary findings, all in the field of health care and medicine Data processing services in the field of health care and medicine Platform as a service (PaaS) featuring computer software platforms for use in health and data analysis and for use in identifying patients who may have had respiratory or pulmonary findings, all in the field of health care and medicine; scientific research for medical purposes in the field of health care and medicine and in the field of respiratory or pulmonary diseases; data collection service using proprietary software to evaluate, analyze and collect data in the field of health care and medicine Medical services; health care services, namely, providing health care information
42 - Scientific, technological and industrial services, research and design
Goods & Services
Platform as a service (PAAS) featuring computer software platforms for early detection of cancer; Software as a service (SAAS) services featuring software for early detection of cancer; Platform as a service (PAAS) featuring computer software platforms for detecting cancer using artificial intelligence; Software as a service (SAAS) services featuring software for detecting cancer using artificial intelligence; Platform as a service (PAAS) featuring computer software platforms for data processing and analysis in the field of health care and medicine; Software as a service (SAAS) services featuring software for data processing and analysis in the field of health care and medicine
86.
IMPLICITLY GUIDED GENERATION BY MATCHING DATA POINTS
An input molecule exhibiting a value for one or more properties may be identified. A molecule design computation model may be applied to generate one or more output molecule exhibiting a different value for the one or more properties than the input molecule. The molecule design computation model may generate the one or more output molecules by at least encoding the input molecule to generate an embedding of the input molecule, and decoding the embedding of the input molecule to generate the one or more output molecules. In some cases, the molecule design computation model may generate the one or more output molecules by denoising an input molecule while conditioned on the input molecule. In some cases, the molecule design computation model may operate on a joint representation of the input molecule that combines a linear and a three-dimensional representation of the input molecule.
An input molecule exhibiting a value for one or more properties may be identified. A molecule design computation model may be applied to generate one or more output molecule exhibiting a different value for the one or more properties than the input molecule. The molecule design computation model may generate the one or more output molecules by at least encoding the input molecule to generate an embedding of the input molecule, and decoding the embedding of the input molecule to generate the one or more output molecules. In some cases, the molecule design computation model may generate the one or more output molecules by denoising an input molecule while conditioned on the input molecule. In some cases, the molecule design computation model may operate on a joint representation of the input molecule that combines a linear and a three-dimensional representation of the input molecule.
An input molecule exhibiting a value for one or more properties may be identified. A molecule design computation model may be applied to generate one or more output molecule exhibiting a different value for the one or more properties than the input molecule. The molecule design computation model may generate the one or more output molecules by at least encoding the input molecule to generate an embedding of the input molecule, and decoding the embedding of the input molecule to generate the one or more output molecules. In some cases, the molecule design computation model may generate the one or more output molecules by denoising an input molecule while conditioned on the input molecule. In some cases, the molecule design computation model may operate on a joint representation of the input molecule that combines a linear and a three-dimensional representation of the input molecule.
An input molecule exhibiting a value for one or more properties may be identified. A molecule design computation model may be applied to generate one or more output molecule exhibiting a different value for the one or more properties than the input molecule. The molecule design computation model may generate the one or more output molecules by at least encoding the input molecule to generate an embedding of the input molecule, and decoding the embedding of the input molecule to generate the one or more output molecules. In some cases, the molecule design computation model may generate the one or more output molecules by denoising an input molecule while conditioned on the input molecule. In some cases, the molecule design computation model may operate on a joint representation of the input molecule that combines a linear and a three-dimensional representation of the input molecule.
An input molecule exhibiting a value for one or more properties may be identified. A molecule design computation model may be applied to generate one or more output molecule exhibiting a different value for the one or more properties than the input molecule. The molecule design computation model may generate the one or more output molecules by at least encoding the input molecule to generate an embedding of the input molecule, and decoding the embedding of the input molecule to generate the one or more output molecules. In some cases, the molecule design computation model may generate the one or more output molecules by denoising an input molecule while conditioned on the input molecule. In some cases, the molecule design computation model may operate on a joint representation of the input molecule that combines a linear and a three-dimensional representation of the input molecule.
Provide herein are methods of treating human patients with familial Alzheimer's disease that result in delayed in symptom onset and/or slowed cognitive decline by administering a humanized monoclonal anti-amyloid beta (Aβ) antibody.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Methods of treating patients having HER2-positive cancer are provided. Certain methods involve treatment of HER2 positive breast cancer using a programmed cell death protein 1 (PD-1) binding antagonist or a programmed death ligand 1 (PD-L1) binding antagonist in combination with trastuzumab and pertuzumab or with trastuzumab emtansine. The treatment regimen may be used in various clinical settings, for example, for treatment in the neoadjuvant or metastatic setting.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A method for generating an output molecule may include determining a three-dimensional target structure representation of a target structure and a noisy latent code. A molecule design computation model may be applied to generate a modified latent code encoding an output molecule molecular occupancy field (or atomic density field) of the output molecule. The molecule design computation model may generate the modified latent code by modifying the noisy latent code such that a three-dimensional structure of the output molecule is consistent with a three-dimensional structure of the target structure. The modified latent code may be decoded to determine the output molecule molecular occupancy field (or atomic density field) of the output molecule. The decoding may include determining, based on the modified latent code, an atomic density exhibited by the output molecule at one or more points in three-dimensional space.
Provided herein are detection reagents and assays for detecting and/or quantitating an analyte in a sample by liquid chromatography/mass spectrometry (LS/MS). In some embodiments, the detection reagent is a compound having the formula wherein: B is a base detection moiety that binds the analyte, L is a cleavable linker, T is a tag suitable for mass spectroscopy, n is an integer greater than or equal to 1, and p is an integer greater than or equal to 1.
Provided herein are detection reagents and assays for detecting and/or quantitating an analyte in a sample by liquid chromatography/mass spectrometry (LS/MS). In some embodiments, the detection reagent is a compound having the formula wherein: B is a base detection moiety that binds the analyte, L is a cleavable linker, T is a tag suitable for mass spectroscopy, n is an integer greater than or equal to 1, and p is an integer greater than or equal to 1.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
The present disclosure provides methods and compositions for treating inflammatory bowel disease (IBD), e.g., ulcerative colitis (UC) or Crohn's disease (CD), with a therapeutic dose of an anti-TNF-like ligand 1A (TL1 A) antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
96.
PREDICTION OF PRECLINICAL PHARMACOKINETICS USING A NEURAL ORDINARY DIFFERENTIAL EQUATION FRAMEWORK
A computer-based method and system for predicting preclinical pharmacokinetics of a therapeutic agent. Dosage regimen data associated with a dosage regimen of a therapy is received. Also received is medical data associated with a subject. Model input data is formed using the dosage regimen data and the medical data. Using a machine learning model and the model input data, a predicted pharmacokinetic (PK) outcome output is generated. The machine learning model may be a neural ordinary differential equation (NODE) system. A recommendation for a clinical trial is formed, using the predicted PK output.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region VL residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the VH of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the VL of the antibody. The altered VH and the VL are expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected. Exemplary dual specific antibodies are also provided as well as methods of using the antibodies.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Disclosed are methods of treating a cancer in a subject using at least one ATR inhibitor and at least one anti-PD(L)1 therapy, wherein the cancer is checkpoint inhibitor non- responsive, a melanoma, or lung cancer.
The invention provides methods for classifying lung cancer (e.g., small cell lung cancer (SCLC), e.g., extensive stage SCLC (ES-SCLC)); methods for treating lung cancer in a patient, for example, by administering a treatment regimen that comprises a PD-1 axis binding antagonist (e.g., atezolizumab) to the patient. Also provided are compositions for use, kits, and articles of manufacture for use in classifying and treating lung cancer in a patient.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
